If you are wondering whether Krystal Biotech's share price still lines up with its underlying value, you are not alone. A closer look at its valuation can help frame that question more clearly. The ...

With no single headline event driving attention today, Scholar Rock Holding (SRRK) is back on watch for many investors as they reassess recent share performance, clinical focus, and the company’s ...

Building an AI infrastructure for biotech. Bacteria that munch on cancer. How to best make a cold brew. All that and more in ...

AI is rewriting biotech’s commercial playbook—cutting waste, shrinking teams, and giving first‑time drugmakers a faster, smarter path to launch.

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. If you are looking at Sotera Health and wondering whether ...

GeneDx is upgraded to 'Buy' as valuation resets and operational improvements support a more realistic growth outlook. Learn ...

In this podcast, Motley Fool analysts Karl Thiel, Tom King, and Tim Beyers discuss: Slow rolling chaos at the FDA and its effects on drug approvals. How to think about risk when investing in biotech.

European biotechs continue to face a demanding investment climate characterised by investor caution. As a result, many are evaluating potential headquarters locations, assessing the types of support ...

This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) has agreed to pay $350 million upfront to partner with Innovent Biologics on the joint development of new therapies targeting cancer and ...

Their makers claim they can detect dozens of cancer types — but some scientists say they could be missing many cancers or ...